Sugi Predict

Sugi Predict / Compounds / SCHEMBL891868

SCHEMBL891868

SCHEMBL891868

CCCCCOC(=O)Nc1ccn([C@]2(O)O[C@H](COC(=O)OCCCCC)[C@@H](OC(=O)OCCCCC)[C@@]2(C)O)c(=O)n1

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.36
▸ PRMT5 O14744 1/20 0.32
▸ WDR77 Q9BQA1 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ PKM P14618 1/20 0.31
▸ ALDH1A1 P00352 2/20 0.31
▸ EPHX2 P34913 1/20 0.30
▸ L3MBTL1 Q9Y468 2/20 0.30
▸ KDM4E B2RXH2 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ CSNK2A2 P19784 1/20 0.30
▸ CSNK2A1 P68400 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL891584 0.93 LMNA (0.36) LMNAPRMT5WDR77CYP1A2CYP2C19
SCHEMBL891694 0.92 LMNA (0.38) LMNAPRMT5WDR77CYP1A2CYP2C19
SCHEMBL891677 0.86 FGFR1 (0.36) ALDH1A1L3MBTL1KDM4E
SCHEMBL891938 0.86 LMNA (0.36) LMNAPRMT5WDR77CYP1A2CYP2C19
SCHEMBL891962 0.85 LMNA (0.38) LMNAPRMT5WDR77CYP1A2CYP2C19
SCHEMBL891166 0.84 LMNA (0.40) LMNAPRMT5WDR77CYP1A2CYP2C19
SCHEMBL5452186 0.79 FGFR1 (0.37) LMNAALDH1A1L3MBTL1KDM4E
SCHEMBL13161001 0.78 LMNA (0.42) LMNAPRMT5WDR77L3MBTL1
SCHEMBL891699 0.78 L3MBTL1 (0.38) LMNAALDH1A1L3MBTL1
SCHEMBL891439 0.73 POLB (0.35) SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120082645-A1 2'-C-METHYL-RIBOFURANOSYL CYTIDINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF XENOPORT, INC. (US) 2012-04-05 — — US claimed
US-8058260-B2 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof XENOPORT, INC. (US) 2011-11-15 — — US claimed
US-20070270374-A1 2'-C-Methyl-Ribofuranosyl Cytidine Prodrugs, Pharmaceutical Compositions and Uses Thereof XENOPORT, INC. 2007-11-22 — — US claimed
US-20120082645-A1 2'-C-METHYL-RIBOFURANOSYL CYTIDINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF XENOPORT, INC. (US) 2012-04-05 — — US disclosed
US-8058260-B2 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof XENOPORT, INC. (US) 2011-11-15 — — US disclosed
US-20070270374-A1 2'-C-Methyl-Ribofuranosyl Cytidine Prodrugs, Pharmaceutical Compositions and Uses Thereof XENOPORT, INC. 2007-11-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120082645-A1 2'-C-METHYL-RIBOFURANOSYL CYTIDINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MTAP, NSUN2, CDA LMNA 1243/4885PRMT5 123/4885WDR77 790/4885
US-20070270374-A1 2'-C-Methyl-Ribofuranosyl Cytidine Prodrugs, Pharmaceutical Compositions and Uses Thereof MTAP, NSUN2, PAICS LMNA 1214/4885PRMT5 130/4885WDR77 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.